SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals informs about board meeting

21 May 2013 Evaluate

Jenburkt Pharmaceuticals has informed that a meeting of board of directors of the company will be held on May 30, 2013, to take on record the audited financial results for the quarter and financial year ended on March 31, 2013, to recommend Dividend, if any and to declare book closure for the ensuing Annual General Meeting.

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1163.20 3.50 (0.30%)
09-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1105.75
Lupin 2263.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×